17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-000336-28-DE (EUCTR)	12/12/2022	28/07/2022	A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: TAK-341 Product Code: TAK-341 INN or Proposed INN: Not assigned Other descriptive name: Human IgG1 monoclonal antibody against alpha-synuclein	Takeda Development Center Americas, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	138	Phase 2	United Kingdom;Italy;Japan;Denmark;Austria;Germany;Portugal;France;United States;Spain
2	NCT05526391 (ClinicalTrials.gov)	November 9, 2022	1/9/2022	A Study of TAK-341 in Treatment of Multiple System Atrophy	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy	Multiple System Atrophy	Drug: TAK-341;Drug: Placebo	Takeda	AstraZeneca	Recruiting	40 Years	N/A	All	138	Phase 2	United States;Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom